Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 18, 2016 (11 years ago)

Nystatin

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: label error on declared strength.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Nystatin, USP Powder for Rx compounding, 150 Million Units, Packaged by Perrigo, Minneapolis MN 55427, NDC 0574-0404-15, UPC 305740404157

Affected NDC 0574-0404-15

Compare with the code on your package — it is the most precise check available.

Drug: Nystatin

Recalling firm
Perrigo Company PLC
NDC code
0574-0404-15
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0652-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nystatin recalls

See all
Class II · Moderate risk

Nystatin Cream USP

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Ongoing Wrong potency / content Padagis US LLC NDC 45802-059-35 D-0677-2026
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024

Other recalls by Perrigo Company PLC

All 2016 recalls
Class II · Moderate risk

Maximum Strength Nasal Spray

CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.

Terminated cGMP deviation Perrigo Company PLC NDC 41250-989-10 D-0629-2022
Class II · Moderate risk

Maximum Strength Nasal Spray

CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.

Terminated cGMP deviation Perrigo Company PLC NDC 41250-989-10 D-0628-2022
Class II · Moderate risk

Sinus Severe

CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.

Terminated cGMP deviation Perrigo Company PLC NDC 55910-696-10 D-0627-2022
Class II · Moderate risk

No Drip Nasal Spray

CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.

Terminated cGMP deviation Perrigo Company PLC NDC 49035-388-10 D-0626-2022